Domainex is set to support Lunac’s discovery project for anticoagulant therapies with reduced bleeding risk, following the developer’s novel target validation.
Xenetic Biosciences says success for Shire’s haemophilia A candidate SHP656 will validate its PolyXen drug delivery technology platform and could net the firm up to $100m.
Clot busting drugs derived from human urine are no more likely to be contaminated with Zika virus than other medicines according to research by the EMA.
International research suggests that a simple in vitro
bioassay, in addition to procedures currently in place, would help
secure the global supply chain for heparin and reduce the risk of
patients being exposed to harmful contaminants.
PEGylation specialist Neose Technologies says that it has now
refocused its R&D focus since the demise of its lead drug
candidate last year, and will concentrate on two drugs for
neutropenia and haemostasis in 2008.
An improved version of Wyeth's haemophilia B treatment BeneFix -
the only recombinant Factor IX product available on the market -
kitted out with a host of new user-friendly features, has been
approved in the EU.
A drug already used to stem bleeding in haemophiliacs cannot be
used to the same effect to treat brain haemorrhages that can cause
strokes, according to its developer Novo Nordisk.
The race to find the next generation of treatments that prevent the
formation of potentially fatal blood clots heated up when
Boehringer Ingelheim announced positive Phase III trial results.
GTC Biotherapeutics and LFB Biotechnologies have entered into a
collaboration, which focuses on recombinant plasma proteins and
monoclonal antibodies (mAbs) to eventually develop a robust
pipeline for treating conditions such as haemophilia.
Researchers have found that a simple and inexpensive test can help
determine which patients with venous thromboembolism (VTE) are at
low risk for recurrence and can therefore avoid unnecessary and
potentially dangerous long-term anticoagulant...
Drug developer Biosante has been awarded a $250,000 (€210,000)
subcontract from the University of Nebraska, Lincoln (UNL), to
develop recombinant Factor IX (FIX) formulations for delivery via
alternative routes of administration,...
Biovitrum and Syntonix have entered into agreement to jointly
develop and commercialise a genetically engineered product to treat
haemophilia, a rare hereditary disorder, which the life expectancy
of haemophilia patients is about...
